Race Oncology activates second site for solid tumour clinical trial

Race Oncology opened patient enrolment at a second site for its Phase 1 clinical trial of RC220 in patients with advanced solid tumours, the company announced on Tuesday.

The Central Coast Local Health District, comprising Gosford and Wyong Hospitals, has been activated following the earlier activation of the lead Australian site, Southside Cancer Centre in Miranda, NSW.

The open-label Phase 1 trial will examine RC220 in combination with doxorubicin in patients with advanced solid tumours, and is set to be conducted across multiple sites in Australia, Hong Kong and South Korea.

Race Chief Executive Officer, Dr Daniel Tillett said the activation of the second clinical site would help accelerate patient recruitment.

“The activation of our second clinical site enables us to accelerate patient recruitment for the Phase 1 clinical trial, aiding the collection of critical safety, tolerability and pharmacokinetics data,” Tillett said.

The study will provide human safety and pharmacokinetic data, identify the maximum tolerated combined dose of RC220 and doxorubicin, and provide initial clinical data on the cardioprotective, anticancer and m6A RNA activities of RC220.

Race’s Phase 1 trial will use ascending doses of RC220 in up to 33 patients in Stage 1 to determine its safety profile. After an interim analysis, the optimal dosage will be assessed in an additional 20 patients in Stage 2.

Patients who are under the care of clinical trial study doctors at recruiting sites can discuss participation with their treating doctor, while those being treated elsewhere should speak with their oncologist about potential referral to a trial site.

The trial details are available on the public clinical trial registry: https://clinicaltrials.gov/study/NCT06815575

Picture: Race Oncology LinkedIn